The Friday afternoon meeting on June 7, 2013, between Sanford “Sandy” Wadler and Norman Schwartz started out like most weekly check-ins between the two Bio-Rad Laboratories Inc. senior executives.
Wadler, the company’s longtime general counsel, walked four doors down the hall in the company’s Northern California headquarters to the office of Schwartz, Bio-Rad’s CEO. Wadler had a seat and began talking about the latest pressing legal issues at the Fortune 1000 life sciences company.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
